Empagliflozin as an adjunctive therapy for type 1 diabetes

Research output: Contribution to journal › Editorial › Other › peer-review

Original language	English
Pages (from-to)	S134
Number of pages	1
Journal	Annals of Translational Medicine
Volume	6
Issue number	S2
DOIs	https://doi.org/10.21037/atm.2018.12.52
Publication status	Published - 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{8e906544b32a4e6e99cead298f4d16ba,

title = "Empagliflozin as an adjunctive therapy for type 1 diabetes",

author = "MacIsaac, \{Richard J.\} and Lee, \{Melissa H.\} and McAuley, \{Sybil A.\} and Ward, \{Glenn M.\} and O'Neal, \{David N\}",

year = "2018",

doi = "10.21037/atm.2018.12.52",

language = "English",

volume = "6",

pages = "S134",

journal = "Annals of Translational Medicine",

issn = "2305-5839",

publisher = "AME Publishing Company",

number = "S2",

}

TY - JOUR

T1 - Empagliflozin as an adjunctive therapy for type 1 diabetes

AU - MacIsaac, Richard J.

AU - Lee, Melissa H.

AU - McAuley, Sybil A.

AU - Ward, Glenn M.

AU - O'Neal, David N

PY - 2018

Y1 - 2018

U2 - 10.21037/atm.2018.12.52

DO - 10.21037/atm.2018.12.52

M3 - Editorial

SN - 2305-5839

VL - 6

SP - S134

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

IS - S2

ER -